600789.SH
鲁抗医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 7.19
−1.91%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.7B | 5.8B | 6.2B | 6.1B | 5.6B |
| Cost of Revenue | 4.4B | 4.5B | 4.7B | 4.6B | 4.4B |
| Gross Profit | 1.3B | 1.3B | 1.5B | 1.5B | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 294.6M | 299.1M | 317.1M | 345.8M | 264.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 256.5M | 256.6M | 234.1M | 232.6M | 212.9M |
| Selling & Marketing Expense | 443.3M | 454.4M | 568.1M | 577.6M | 475.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.1B | 1.2B | 1.3B | 1.1B |
| Cost and Expenses | 5.6B | 5.6B | 6.0B | 5.9B | 5.5B |
| Operating Income (EBIT) | 140.8M | 160.6M | 436.2M | 272.1M | 148.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 141.9M | 161.2M | 433.9M | 273.0M | 150.1M |
| Income Tax Expense | 55.8M | 49.3M | 25.6M | 16.2M | 7.0M |
| Bottom Line | |||||
| Net Income | 87.0M | 112.3M | 394.6M | 246.2M | 138.0M |
| Earnings from Cont. Ops | 86.1M | 111.9M | 408.3M | 256.8M | 143.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 87.0M | 112.3M | 394.6M | 246.2M | 138.0M |
| Per Share | |||||
| Basic EPS | CN¥0.09 | CN¥0.12 | CN¥0.44 | CN¥0.28 | CN¥0.16 |
| Diluted EPS | CN¥0.09 | CN¥0.12 | CN¥0.44 | CN¥0.28 | CN¥0.15 |
| Revenue Per Share | CN¥5.36 | CN¥6.16 | CN¥6.95 | CN¥6.99 | CN¥6.52 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 935.9M | 896.9M | 879.2M | 862.6M |
| Diluted Shares Outstanding | 1.1B | 935.9M | 896.9M | 879.2M | 862.6M |
| Profitability Metrics | |||||
| EBITDA | — | 610.1M | 838.2M | 654.7M | 498.8M |
| D&A | — | 449.5M | 402.0M | 382.6M | 350.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026